Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
about
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolismMethods for administering subcutaneous heparin during pregnancyMethods for administering subcutaneous heparin during pregnancyVTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDiagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice GuidelinesOral anticoagulants: pharmacodynamics, clinical indications and adverse effectsPatients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatmentArterial thrombosis in ulcerative colitis. Transcatheter thrombolytic therapyLong-term anticoagulation. Indications and management.Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of lifeVitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.Intracerebral haemorrhages and oral anticoagulation in the north of Scotland.Problems in laboratory monitoring of heparin dosage.Coagulation and cancer: implications for diagnosis and management.Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin.Low-molecular-weight heparins: weeks or months instead of days of treatment.Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Therapeutic ranges in anticoagulant administration.Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology.Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event--first year and long-term comparative mortality.Managing disability from stroke.Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin.Acute venous thrombosis. Therapeutic choices for superficial and deep veins.Anticoagulation. Current approach to heparin and warfarin therapy.Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.New anticoagulants for the treatment of venous thromboembolism.Venous thromboembolism: epidemiology, diagnosis, prevention.Low-molecular-weight heparins for the treatment of venous thromboembolism.Antiphospholipid antibody associated thrombosis: a consensus for treatment?Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service.Oral anticoagulants reassessed.Atrial fibrillation and embolism.Venous filling defects on portal venous phase CT of the abdomen and pelvis: clinical implications and positive predictive value for diagnosing deep venous thrombosis.Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis.Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.
P2860
Q24198032-510B1A60-892F-48BA-B9A9-F3063AAB8711Q24198812-C11D03E7-3E6B-4AD6-B1B0-8DD54AF428D4Q24234862-7EEC827C-13A0-4AEA-A611-7C638A592661Q24632982-3A2755DE-AFFC-46A5-A49F-6D1B936163EAQ24633053-CA9E5F37-B6A1-4BD9-8964-6FC46CE39850Q28072833-9706207D-1552-4B57-A047-EA8EE161320EQ28319507-0C223587-07A5-4CCC-8198-A88434BA1D1BQ33565796-F4F3D0AC-2228-4BF1-9486-97521DCCF757Q33608695-A2AD4E7C-8ABD-40DC-A8A6-803D649335CBQ33617257-B58EF8C1-E044-4984-9C84-A7185132F53DQ33962232-E9FCE178-6449-4714-8228-655CB7313E5AQ34062340-DB82BF99-40F7-4C33-883A-5C0EA315F5B1Q34075223-B9BFFC4F-9AD0-4BE5-BF2B-6A5CAA535B54Q34106860-EAECCC42-446D-48EB-89A8-1CC9C989E2C9Q34138190-B8E257A1-8E93-4C43-8162-7D9B03AC1787Q34183316-53720AF8-8A1B-43E4-97B4-F36F7EF2BEF6Q34430449-756534BA-8D94-426F-BAF2-623EE6AC7DB7Q34437785-5C0C81A1-3645-4791-8B69-A80907CFB35FQ34485668-865C9BDC-7BD9-40F6-8E61-5378175F1B65Q35582723-635D7E9C-3B24-4347-8714-5B53912DAAF8Q36056593-6CA854DE-F039-4E47-88E2-602B45848DCBQ36471056-7C553083-7C74-4A34-9110-2C16DFCC4605Q36518674-EFC8744A-74BB-4635-9028-6119E1622401Q36576216-E60E1C5A-3304-4500-BF5C-74DCE895B062Q36951531-643FDC0B-43E2-44A6-BDB8-4A127A46D47EQ37716752-C5AAFEE1-FDDB-4AF0-8BF7-1C695F637BC5Q38522270-A3A8F2A5-FE7A-4679-A8CE-8A2A249B1878Q38664988-9FABA5F4-0294-47C5-9E8F-0DD0C3A4669AQ38831847-3575B1CE-21FC-4036-AEF4-1CE45044C38EQ39592542-4E6C71A9-AB81-45A0-8AFE-C1574E33C13BQ40785363-806655F3-BE85-4B4C-9C3B-57C1A2BC74ABQ41442948-6E7CB56A-6AF1-4F1A-BAC6-CF3E0507208EQ41741268-BF818624-77D1-46D8-9004-AC852A176E6FQ42335666-1CB17919-6E90-47ED-A0A9-B44E68DED46FQ42777616-EEF2A216-13E4-4EA7-A3D9-70E3C2538D71Q43449073-07F8B3E3-CCBF-4087-BDA4-E81FD36F6DF9Q46428749-EB3F1D61-D93F-41A4-81F9-073113607C3DQ46917499-56499346-823D-41F2-817F-534ACDFC57F7Q47330935-9065023F-098A-4674-9F8C-3D2B31D6CB53Q47834396-ED4D40EF-CD12-48C1-BECB-753BD7013A3B
P2860
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh-hant
name
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@en
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@nl
type
label
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@en
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@nl
prefLabel
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@en
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@nl
P2093
P1476
Adjusted subcutaneous heparin ...... reatment of venous thrombosis.
@en
P2093
McLaughlin D
P304
P356
10.1056/NEJM198201283060401
P407
P577
1982-01-01T00:00:00Z